Postdoc: Genome-Engineered hiPSC for Cell Therapy

A*STAR RESEARCH ENTITIES; Singapore; On-site; SGD 60,000 - 90,000; Full time

Job summary

A Post Doctoral Fellow position at A*STAR RESEARCH ENTITIES focuses on generating genome-engineered induced pluripotent stem cells (hiPSCs) for cell therapy and translational aims. You will lead hands‑on experiments, optimize non‑viral targeting tools, and contribute to a platform for hypoimmunogenic hiPSC lines suitable for allogeneic therapy.

Collaboration with industrial partners is central to the project.

Qualifications

• Expert knowledge of laboratory-based methodologies such as nucleic acid extraction, molecular cloning, human pluripotent stem cell culture & differentiation
• Extensive experience with human pluripotent stem cell culture and genome editing is preferred
• Good organizational skills and ability to multitask
• Highly motivated, keen to learn and committed to laboratory work
• Able to work independently and as part of a team
• Good communication (verbal and written) and presentation skills
• Experience with computational work flows is preferred

Responsibilities

• Lead the hands-on experiments and operations to engineer human cells
• Follow analytical procedures and instrumental operation guidelines
• Perform data collection and manage research data and notes
• Assist the team with the maintenance of smooth and safe operation in the working environment
• Ensure project deliverables are met in a timely manner and to the highest standard

Skills

Hands-on lab leadership

Nucleic acid techniques

Molecular cloning

Pluripotent stem cell culture

Genome editing

Data management

Independent and team work

Communication and presentation

Computational workflows

Tools

Nucleic acid extraction

Molecular cloning

PSC culture & differentiation

Job description

A Post Doctoral Fellow position at A*STAR RESEARCH ENTITIES focuses on generating genome-engineered induced pluripotent stem cells (hiPSCs) for cell therapy and translational aims. You will lead hands‑on experiments, optimize non‑viral targeting tools, and contribute to a platform for hypoimmunogenic hiPSC lines suitable for allogeneic therapy.

Collaboration with industrial partners is central to the project.